207 related articles for article (PubMed ID: 2413308)
1. Antagonism of vasopressin-induced coronary artery constriction by the vasopressin antagonist d(CH2)5Tyr(Me)-AVP.
Kopia GA; Valocik RE
J Cardiovasc Pharmacol; 1985; 7(5):958-63. PubMed ID: 2413308
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of leukotriene D4-induced coronary vasoconstriction by leukotriene antagonists in the anesthetized dog.
Kopia GA; Valocik RE; Torphy TJ; Cieslinksi LB; Sarau HM; Foley JJ; Wasserman MA
J Pharmacol Exp Ther; 1987 Apr; 241(1):174-80. PubMed ID: 2437287
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic effects of antagonists of the vasoconstrictor action of vasopressin in conscious dogs.
Liard JF; Spadone JC
J Cardiovasc Pharmacol; 1984; 6(4):713-9. PubMed ID: 6206331
[TBL] [Abstract][Full Text] [Related]
4. Coronary vasoconstriction produced by vasopressin in anesthetized goats. Role of vasopressin V1 and V2 receptors and nitric oxide.
Fernández N; García JL; García-Villalón AL; Monge L; Gómez B; Diéguez G
Eur J Pharmacol; 1998 Jan; 342(2-3):225-33. PubMed ID: 9548390
[TBL] [Abstract][Full Text] [Related]
5. Direct cardiac effects of vasopressin: role of V1- and V2-vasopressinergic receptors.
Walker BR; Childs ME; Adams EM
Am J Physiol; 1988 Aug; 255(2 Pt 2):H261-5. PubMed ID: 2970231
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological evaluation of d(CH2)5Tyr(Me)AVP as an antagonist of vasopressin-induced contraction of the isolated rat caudal artery.
Clineschmidt BV; Lis EV
Arch Int Pharmacodyn Ther; 1986 Nov; 284(1):72-84. PubMed ID: 2950833
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
Manning M; Stoev S; Bankowski K; Misicka A; Lammek B; Wo NC; Sawyer WH
J Med Chem; 1992 Jan; 35(2):382-8. PubMed ID: 1531076
[TBL] [Abstract][Full Text] [Related]
8. Central and systemic effects of a vasopressin V1 antagonist on MAP recovery after haemorrhage in rats.
Johnson JV; Bennett GW; Hatton R
J Cardiovasc Pharmacol; 1988 Oct; 12(4):405-12. PubMed ID: 2465440
[TBL] [Abstract][Full Text] [Related]
9. Comparison of selective arginine vasopressin V1 and V2 receptor antagonists on burn shock in the rat.
Sun K; Lin BC; Wang CH; Zhu HN
Cardiovasc Res; 1991 Apr; 25(4):265-9. PubMed ID: 1884385
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of the depressor action of LY171555, a selective dopamine D2 receptor agonist, in the anesthetized rat.
Nagahama S; Chen YF; Lindheimer MD; Oparil S
J Pharmacol Exp Ther; 1986 Nov; 239(2):426-32. PubMed ID: 3772802
[TBL] [Abstract][Full Text] [Related]
11. Short-term hemodynamic effects of vasopressin V1-receptor inhibition in chronic right-sided congestive heart failure.
Stone CK; Liang CS; Imai N; Sakamoto S; Sladek CD; Hood WB
Circulation; 1988 Nov; 78(5 Pt 1):1251-9. PubMed ID: 3180381
[TBL] [Abstract][Full Text] [Related]
12. Development of high sodium renal hypertension during chronic blockade of the vascular effects of vasopressin.
Hinojosa C; Haywood JR
J Pharmacol Exp Ther; 1986 Aug; 238(2):492-6. PubMed ID: 2874211
[TBL] [Abstract][Full Text] [Related]
13. Role of vasopressin in renal vascular changes with hypoxemia and hypercapnic acidosis in conscious dogs.
Rose CE; Ragsdale NV; Carey RM
Am J Physiol; 1990 Oct; 259(4 Pt 2):R690-702. PubMed ID: 2145777
[TBL] [Abstract][Full Text] [Related]
14. Blood pressure and heart rate effect of a vasopressin antagonist in conscious normotensive rats pretreated with exogenous vasopressin.
Waeber B; Nussberger J; Brunner HR
Eur J Pharmacol; 1983 Jul; 91(1):135-7. PubMed ID: 6688586
[TBL] [Abstract][Full Text] [Related]
15. Comparative cardiac effects of terlipressin, vasopressin, and norepinephrine on an isolated perfused rabbit heart.
Ouattara A; Landi M; Le Manach Y; Lecomte P; Leguen M; Boccara G; Coriat P; Riou B
Anesthesiology; 2005 Jan; 102(1):85-92. PubMed ID: 15618791
[TBL] [Abstract][Full Text] [Related]
16. Prolonged inhibition of pressor response to vasopressin by a potent specific antagonist, [1-(beta-mercapto-beta, beta-cyclopentamethylenepropionic acid) 2-(O-methyl)tyrosine]arginine-vasopressin.
Pang CC; Leighton KM
Can J Physiol Pharmacol; 1981 Sep; 59(9):1008-12. PubMed ID: 6895346
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic effects of neurohypophyseal peptides with antidiuretic activity in dogs.
Schwartz J; Liard JF; Ott C; Cowley AW
Am J Physiol; 1985 Nov; 249(5 Pt 2):H1001-8. PubMed ID: 3840655
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of arginine vasopressin on isolated guinea pig heart function during perfusion at constant flow and constant pressure.
Graf BM; Fischer B; Martin E; Bosnjak ZJ; Stowe DF
J Cardiovasc Pharmacol; 1997 Jan; 29(1):1-7. PubMed ID: 9007663
[TBL] [Abstract][Full Text] [Related]
19. Evidence for a vasodilatory effect of vasopressin in the conscious rat.
Walker BR
Am J Physiol; 1986 Jul; 251(1 Pt 2):H34-9. PubMed ID: 3755295
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and some pharmacological properties of 18 potent O-alkyltyrosine-substituted antagonists of the vasopressor responses to arginine-vasopressin.
Manning M; Lammek B; Bankowski K; Seto J; Sawyer WH
J Med Chem; 1985 Oct; 28(10):1485-91. PubMed ID: 4045923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
